Precision treatment for inoperable liver cancer
Part of Cancer clinical trials.
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You should not have had any prior treatment for liver cancer.
- Your liver function must be fairly good (Child-Pugh score 7 or less).
- You must be able to do daily activities with little or no help (ECOG 0-1).
- Your tumor must be confirmed as liver cancer by biopsy and cannot be removed with surgery.
- A special computer analysis of your tumor tissue, scans, and genetic data must show you are likely to benefit from the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial compares two ways to deliver chemotherapy into the liver—TACE (a targeted injection that blocks blood flow) and HAIC (a continuous infusion through a small tube)—along with an immunotherapy drug (PD-1 inhibitor) and a targeted therapy pill (lenvatinib). It's for people with liver cancer that cannot be removed by surgery.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Precision Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.